Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024 17:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at Upcoming Investor Conferences
August 06, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024 17:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 06, 2024 16:01 ET | Travere Therapeutics, Inc.
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 29, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024 17:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at Upcoming Investor Conferences
February 26, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024 16:01 ET | Travere Therapeutics, Inc.
Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S....
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 08, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15,...